Summary
In a significant market movement during October 2023, Laverock Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £13,500,000. Leading the round was Eli lilly and company, UK Innovation & Science Seed Fund, Tekfen Ventures, Maven Capital Partners, Calculus Capital, EOS Ventures, Mercia Ventures.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Eli lilly
Lead Investor / Acquirer
company
Lead Investor / Acquirer
UK Innovation
Lead Investor / Acquirer
Science Seed Fund
Lead Investor / Acquirer
Tekfen Ventures
Lead Investor / Acquirer
Maven Capital Partners
Lead Investor / Acquirer
Calculus Capital
Lead Investor / Acquirer
EOS Ventures
Lead Investor / Acquirer
Mercia Ventures
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Seed prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in